Reverse Transcriptase Inhibitors: all 1,328 studies that test it

Page 8 of 14. Open to participants first (42), then studies with results posted, then the rest; newest registration first within each.

• Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination TabletsCompletedNCT01366547Phase 1
• A Study Evaluating the Efficacy of Glucocorticoids in Patients With Pre-ACLF-HBVStatus unknownNCT01344174Not applicable
• Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC TherapyStatus unknownNCT01341743Phase 4
• TMC125IFD1001 - Drug-Drug Interaction of Etravirine With Telaprevir and TMC278 With Telaprevir.CompletedNCT01336829Phase 1
• Rollover Protocol Continued Access to Tenofovir Disoproxil Fumarate (TDF) for Subjects in TaiwanCompletedNCT01334567Phase 2
• Safety and Efficacy of Raltegravir+TDF+3TC in HBV/HIV Co-infected PatientsStatus unknownNCT01318096Not applicable
• TMC278-TiDP6-C153 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC278 and RaltegravirCompletedNCT01288755Phase 1
• Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy VolunteersCompletedNCT01285388Phase 1
• Microbicide Safety and Acceptability in Young MenCompletedNCT01283360Phase 1
• Influence of Nevirapine on HCV Viral LoadStatus unknownNCT01277627Not applicable
• Dose-Proportionality and Intra-Individual Variability of Intracellular TFV-DP and FTC-TP in Healthy VolunteersCompletedNCT01276600Phase 1
• Metabolic Effects of Atazanavir/Ritonavir Versus Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine in naïve HIV-1 Infected PatientsCompletedNCT01274780Phase 4
• The Intensive Pharmacokinetics Sub-study of Encore1 (ENCORE1-PK)CompletedNCT01271894Phase 3
• A Phase I, Open-label Trial to Explore the Pharmacokinetics, Safety and Tolerability of TMC278 (Rilpivirine) 25 mg Once Daily Following a 2-week Period Receiving Efavirenz, in Healthy Male and Female VolunteersCompletedNCT01268839Phase 1
• A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Patients With Chronic Hepatitis BTerminatedNCT01264133Phase 4
• A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Proportion to Roadmap Concept in Patients With HBV Associated-HCCCompletedNCT01263002Phase 4
• Randomized Controlled Study of Tenofovir Plus Telbivudine Versus Monotherapy With Either Drug in HBeAg Negative Chronic Hepatitis B PatientsWithdrawnNCT01260610Not applicable
• Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir -Boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)- Naive Adults or Adults Recommencing ART.CompletedNCT01258439Phase 4
• TMC435-TiDP16-C123 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents Efavirenz and RaltegravirCompletedNCT01241773Phase 1
• Rectal Safety and Acceptability Study of Tenofovir 1% GelCompletedNCT01232803Phase 1
• TMC435-TiDP16-C114 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents TMC278 and TenofovirCompletedNCT01205139Phase 1
• PI or NNRTI as First-line Treatment of HIV in West Africa - the PIONA TrialCompletedNCT01192035Phase 4
• Pharmacokinetic Study to Investigate Low-dose Combinations of a Cocktail of Seven Drugs for Simultaneous Phenotyping of CytochromesCompletedNCT01187862Phase 1
• A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear CellsWithdrawnNCT01173510Phase 4
• Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Tenofovir To Abacavir In Hiv-1-Infected Subjects With Loss Of Bone Mineral DensityCompletedNCT01153217Phase 3
• Tenofovir Gel in Pregnancy and LactationCompletedNCT01136759Phase 1
• Plasma and Intracellular Concentrations of Raltegravir and Etravirine Administered Once DailyCompletedNCT01121809Phase 4
• The First Failure StudyTerminatedNCT01118871Phase 4
• Safety Study of Isentress® + Truvada® in Post-exposure Treatment of HIV InfectionCompletedNCT01114425Phase 3
• PK of Tenofovir, Emtricitabine and Efavirenz in Healthy VolunteersCompletedNCT01108926Phase 1
• GSK1349572 Drug Interaction Study With EfavirenzCompletedNCT01098526Phase 1
• TMC125HIV1083 - Swallowability of Uncoated 200 mg Etravirine Tablets in HIV-1 Infected PatientsCompletedNCT01090648Phase 1
• A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D.CompletedNCT01088659Phase 3
• Clinical Study of an Aluvia-based HAART Regimen for Prevention of Mother-to-child HIV Transmission in AfricaCompletedNCT01088516Phase 4
• Efficacy Optimizing Research of Lamivudine TherapyCompletedNCT01088009Phase 4
• Randomized Controlled Trial of Tenofovir in Patients of Reactivation of Hepatitis B Presenting as Acute on Chronic Liver FailureCompletedNCT01074645Phase 4
• Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected PatientsCompletedNCT01059422Phase 4
• Pre-Exposure Prophylaxis Using TMC278LATerminatedNCT01049932Phase 1/2
• Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral TherapyStatus unknownNCT01049685Phase 4
• A Pilot Study of Kaletra and Intelence Tablets in Naive SubjectsCompletedNCT01045369Phase 4
• Evaluation of the Cellular Pharmacology of Tenofovir and Emtricitabine According to HIV Infection StatusCompletedNCT01040091Phase 1
• Switching From Protease Inhibitor (PI) to Etravirine in HIV-1 Infected Subjects With Viremia SuppressionCompletedNCT01034917Phase 3
• Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)CompletedNCT01033760Phase 3
• Appropriate Timing of HAART in Co-infected HIV/TB PatientsTerminatedNCT01014481Phase 4
• Lamivudine Therapy in Patients With Prior Entecavir Treatment and Undetectable Viral LoadCompletedNCT01013272Not applicable
• Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) PatientsSuspendedNCT01010373Phase 2
• Telbivudine Versus Lamivudine for Maintenance Therapy of Patients With Chronic Hepatitis B and Negative HBV Viral Load After 6 Month of Treatment With TelbivudineTerminatedNCT01005238Phase 4
• TMC278-TiDP6-C154: Evaluation of the Possible Influence of Omeprazole Intake - and the pH Increase in the Stomach Triggered by Omeprazole Intake - on the Blood Levels of TMC278 in Healthy VolunteersCompletedNCT01001247Phase 1
• Simvastatin for the Treatment of Chronic Hepatitis BCompletedNCT00994773Phase 1
• Safety, Tolerability, and Effect of TMC207 and Efavirenz in Healthy VolunteersCompletedNCT00992069Phase 1
• Entecavir Plus Adefovir in Lamivudine-Resistant PatientsWithdrawnNCT00986778Phase 4
• Pharmacokinetics of Lamivudine at Two Different DosesCompletedNCT00985647Phase 1/2
• Rectal Microbicide Safety and Acceptability Trial of Topically Applied Tenofovir Compared With Oral TabletCompletedNCT00984971Phase 1
• Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected WomenWithdrawnNCT00984152Phase 3
• Hepatitis B Surface Antigen(HBsAg) Loss in Chronic Hepatitis B Patients With Low Viral LoadCompletedNCT00973219Not applicable
• A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-Risk Populations in Kenya, AfricaCompletedNCT00971230Phase 1/2
• CD4 Cell Recovery in HIV-1 Patients Comparing 2 Treatment RegimesCompletedNCT00966160Phase 3
• TACE and Adefovir Compared With Transarterial Chemoembolization (TACE) Alone for Hepatitis B Virus (HBV)-Related Unresectable Hepatocellular Carcinoma (HCC)Status unknownNCT00960518Phase 2
• Efficacy and Safety of Oltipraz in the Patients With Liver Fibrosis and CirrhosisCompletedNCT00956098Phase 2
• HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta HepatitisCompletedNCT00932971Phase 2
• A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-risk Populations in Uganda, AfricaCompletedNCT00931346Phase 1/2
• Topical Application of AS101 for the Treatment of Atopic DermatitisTerminatedNCT00927212Phase 2
• Application of AS101 for the Treatment of Thrombocytopenia in Solid Tumor PatientsTerminatedNCT00926354Phase 2
• TMC207-TiDP13-C117: Interaction Study in Human Immunodeficiency Virus-type 1 (HIV-1) Infected Patients With Nevirapine (NVP)CompletedNCT00910806Phase 1
• Examining Hair to Determine Tenofovir ExposureCompletedNCT00903084Phase 1
• Disulfiram Interactions With HIV Medications: Clinical ImplicationsCompletedNCT00878306Phase 1
• GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/RitonavirCompletedNCT00867152Phase 1
• Raltegravir Activity In Lymphoid TissuesWithdrawnNCT00863668Not applicable
• Study in Healthy Males to Measure Darunavir and Etravirine in Blood, Seminal Fluid, and Rectal TissueCompletedNCT00855088Phase 1
• A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in ZimbabweCompletedNCT00834457Phase 2/3
• TMC125-TiDP2-C188: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Effect of Multiple-dose TMC125 on Buprenorphine and Norbuprenorphine Administered in HIV-negative Patients on Stable Buprenorphine/Naloxone Maintenance Therapy.CompletedNCT00828815Phase 1
• TMC278-TiDP38-C145: A Bioavailability Study in Healthy Adult Volunteers to Evaluate 3 Pediatric Formulations of TMC278 (a Solution, a Suspension, and Granules) Compared to an Adult Tablet FormulationCompletedNCT00812292Phase 1
• Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV InfectionStatus unknownNCT00810524Phase 4
• Efficacy of Clevudine Plus Lamivudine for Lamivudine-resistant Chronic Hepatitis B PatientsTerminatedNCT00798460Phase 4
• Patient Preference, Sleep Quality, and Anxiety/Depression: A Randomized Comparison of Etravirine and EfavirenzCompletedNCT00792584Not applicable
• Pilot Study Switching Individuals Receiving EFV With Continuing Central Nervous System Toxicity to TMC125CompletedNCT00792324Phase 3
• Topical Application of AS101 for the Treatment of PsoriasisWithdrawnNCT00788424Phase 2
• Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected PatientsWithdrawnNCT00782301Phase 4
• Bioequivalence Study of Zidovudine 300 mg Tablets, USP Under Fed ConditionsCompletedNCT00779376Not applicable
• Bioequivalence Study of Zidovudine 300 mg Tablets, USP Under Fasting ConditionsCompletedNCT00779233Not applicable
• ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation TrialCompletedNCT00772902Phase 4
• TMC125-TiDP2-C197: A Phase I Trial to Investigate the Pharmacokinetic Interaction Between Lopinavir/Ritonavir and TMC125 Both at Steady-state in Healthy Volunteers.CompletedNCT00767117Phase 1
• Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid MetabolismStatus unknownNCT00759070Phase 4
• TMC278-TiDP6-C152: A Study to Assess the Effects of TMC278 and Efavirenz (EFV) on the QT/QTc Interval (Heart Conduction and Heart Rhythm) in Healthy Volunteers.CompletedNCT00744809Phase 1
• TMC278-TiDP6-C121: Drug-drug Interaction Trial to Investigate the Potential Interaction Between TMC278 25 mg Daily and Methadone, at Steady State.CompletedNCT00744770Phase 1
• TMC278-TiDP15-C150: Trial to Examine Safety, Tolerability and Plasma Pharmacokinetics of Multiple Doses of TMC278LA.TerminatedNCT00741741Phase 1
• TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects.CompletedNCT00740389Phase 1
• Pilot Study With Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Treatment Naive HIV-Infected SubjectsStatus unknownNCT00740064Phase 4
• TMC278-TiDP6-C136: Effect of TMC278 on Ethinylestradiol and Norethindrone in Healthy Women.CompletedNCT00739622Phase 1
• TMC278-TiDP6-C130: Pharmacokinetics, Safety and Tolerability of TMC278 in Subjects With Mildly or Moderately Impaired Hepatic Function.CompletedNCT00736905Phase 1
• Genetic Determinants of the Metabolism of Non-nucleoside Reverse Transcriptase InhibitorsCompletedNCT00730223Phase 1
• GSK1349572 Drug Interaction With TenofovirCompletedNCT00726336Phase 1
• Differences in Malaria Infection Levels in HIV-infected Infants and Children Receiving PI- and NNRTI-based HAARTCompletedNCT00719602Early Phase 1
• VENICE Study Nevirapine Full Dose/Dose EscalationCompletedNCT00704249Phase 4
• Durability of Nevirapine-Based Antiretroviral RegimenCompletedNCT00703898Phase 4
• Pharmacokinetic Interactions Between Antiretroviral Agents and Antimalarial Drug CombinationsCompletedNCT00697892Phase 1
• An Open-Label Treatment Protocol to Provide Continued Elvucitabine TreatmentCompletedNCT00675844Phase 2
• Safety and Pharmacokinetic Study of Fixed Dose Combination of Zidovudine, Lamivudine, and Nevirapine in HIV-Infected Children in ThailandCompletedNCT00672412Phase 1/2
• A 72-week Randomized Clinical Trial Comparing the Safety and Efficacy of Three Initial Antiretroviral Regimens -GPO-VIR S (d4T/3TC/NVP) for 24 Weeks Followed by GPO-VIR Z (AZT/3TC/NVP) vs GPO-VIR Z vs TDF/FTC/NVPCompletedNCT00669487Phase 3
• Bioequivalence Study of Didanosine in Children Treated for HIVSuspendedNCT00668356Phase 2

← Reverse Transcriptase Inhibitors overview